5-Amino-1MQ in Canada: A Research Guide to the NNMT Inhibitor and NAD⁺ Salvage Pathway

Why 5-Amino-1MQ deserves a dedicated research guide#

5-Amino-1MQ Canada searches are still relatively low in absolute volume compared with the dominant GLP-1 peptide queries, but they are rising on a steeper trajectory than many older metabolic compounds. The reason is that 5-Amino-1MQ represents a fundamentally different mechanistic entry point into body-composition research. While Retatrutide, Semaglutide, and Tirzepatide act on incretin and glucagon receptors to suppress appetite and delay gastric emptying, and while AOD-9604 targets beta-3-adrenergic-mediated lipolysis without IGF-1 stimulation, 5-Amino-1MQ acts inside the adipocyte itself by inhibiting a single methyltransferase enzyme and restoring NAD⁺ and SAM pools. That intracellular metabolic correction is distinct enough to warrant its own research programme, its own sourcing standards, and its own guide.

Northern Compound places 5-Amino-1MQ in the weight-management archive because the dominant search intent is metabolic: researchers want compounds that influence adipose tissue biology, energy balance, and body composition. But the responsible framing is narrower and more precise than that. 5-Amino-1MQ is not a peptide in the traditional sense. It is a small-molecule quinolinium derivative that happens to be sold alongside peptides in many research catalogues, and its mechanism is enzymatic rather than receptor-directed. A good research guide should explain what NNMT is, why adipose tissue expresses it at pathologically high levels in obesity, how inhibiting it alters the metabolome, what the strongest preclinical data show, and what a Canadian lab should verify before using the compound.

This article treats 5-Amino-1MQ as research-use-only material. It does not provide dosing instructions for humans, injection guidance, obesity-treatment advice, or personal-use recommendations. The purpose is to map the evidence, clarify the mechanism, distinguish the compound from both GLP-1 agonists and GH fragments, and set sourcing standards that match its actual development stage.

What 5-Amino-1MQ is at the molecular level#

5-Amino-1MQ is the systematic name for 5-amino-1-methylquinolinium, a quinolinium-based small molecule with a primary amine substitution at the 5-position of the quinoline ring and a methyl group on the quaternary nitrogen. Its molecular formula is C₁₀H₁₀N₂ and its molecular weight is 158.20 Da as the free base. In many supplier preparations it is supplied as a salt—commonly chloride, bromide, or iodide—raising the apparent molecular weight depending on the counter-ion.

The compound was designed by Neelakantan and colleagues at the University of Texas Medical Branch as part of a structure-guided medicinal-chemistry effort against nicotinamide N-methyltransferase (NNMT). The starting scaffold was 1-methylquinolinium (1-MQ), a weak and impermeable NNMT inhibitor. By introducing primary amine substituents at positions 5 and 7, the team achieved two simultaneous improvements: a roughly ten-fold boost in inhibitory potency (IC₅₀ from 12.1 µM for 1-MQ down to 1.2 µM for 5-amino-1MQ) and a dramatic increase in membrane permeability, as measured by parallel artificial membrane permeability assay (PAMPA) and bidirectional Caco-2 transport.

NNMT as the pharmacological target#

NNMT (EC 2.1.1.1) is a cytosolic methyltransferase that transfers a methyl group from S-adenosylmethionine (SAM) to the pyridine nitrogen of nicotinamide, producing N-methylnicotinamide (MNA) and S-adenosylhomocysteine (SAH). In most tissues NNMT is expressed at low levels, but in white adipose tissue (WAT) its expression is markedly elevated in obesity. A 2014 study by Kannt and colleagues demonstrated that NNMT knockdown in adipocytes reduced intracellular MNA, increased NAD⁺ and SAM, and improved insulin-stimulated glucose uptake. Those findings validated NNMT as a druggable target for metabolic disease.

The mechanism is not merely about blocking a single enzymatic step. NNMT sits at a critical metabolic node where the NAD⁺ salvage pathway, the one-carbon methyl-donor pool, and the methionine cycle intersect. When NNMT is overactive in adipocytes:

1. Nicotinamide is consumed rather than recycled into NAD⁺ via NAMPT, lowering the NAD⁺/NADH ratio and reducing sirtuin activity.
2. SAM is depleted because each MNA molecule produced costs one methyl group from SAM.
3. SAH accumulates, and because SAH inhibits most methyltransferases, the elevated SAH/SAM ratio suppresses the broader cellular methylome.
4. The net effect is a metabolically impaired adipocyte poised for insulin resistance, lipogenesis, and inflammation.

5-Amino-1MQ reverses this cascade by inhibiting NNMT. The result, in preclinical models, is restoration of NAD⁺ and SAM, reduction of adipose tissue mass, and improved metabolic parameters.

Analytical identity and verification#

Because 5-Amino-1MQ is a small molecule rather than a peptide, its analytical verification follows a different template from the standard peptide COA. Canadian researchers should nonetheless expect rigorous documentation:

1. HPLC purity: A reversed-phase or ion-pairing chromatogram showing the principal peak at the expected retention time, with integration percentage and peak purity assessment. Because quinolinium compounds are ionic, standard C18 reversed-phase methods may require ion-pairing reagents such as heptafluorobutyric acid (HFBA).
2. Mass spectrometry: Electrospray MS confirming the expected molecular ion. For the chloride salt, the cationic quinolinium species appears at m/z 159.08, with the corresponding chloride adduct or counter-ion pattern in the negative mode.
3. NMR spectroscopy (1H and 13C): Characteristic aromatic signals in the quinoline region, with the exocyclic methyl group on the pyridine nitrogen appearing as a singlet at approximately 4.2–4.4 ppm in the 1H spectrum.
4. Residual solvent and heavy-metal screening: Particularly for syntheses involving quaternisation with methyl iodide or dimethyl sulfate, residual alkylating agents should be below detectable limits.
5. Counter-ion content: The exact salt form (chloride, bromide, iodide) should be stated, and the stoichiometry confirmed by elemental analysis or ion chromatography.
6. Storage and stability: Quinolinium salts are generally stable as dry powders at room temperature but should be protected from light and moisture to prevent oxidation or hydration.

Researchers should not accept a vial labelled generically as "1MQ" or "methylquinolinium" without confirmation of the exact positional isomer (5-amino versus 7-amino or unsubstituted 1-MQ), because potency and permeability differ markedly between isomers.

Mechanism: restoring NAD⁺ and SAM in adipose tissue#

The mechanistic story of 5-Amino-1MQ is inseparable from the biology of NNMT in adipose tissue. Without understanding that biology, the compound is easy to mischaracterise as a generic "fat burner" or to conflate with unrelated NAD⁺ precursors such as NMN or NR. The actual mechanism is subtler and more specific.

The NAD⁺ salvage pathway in obesity#

NAD⁺ is synthesised in mammals through three routes: de novo synthesis from tryptophan, the Preiss–Handler pathway from nicotinic acid, and the salvage pathway from nicotinamide. The salvage pathway is the most quantitatively important in most tissues, and its rate-limiting enzyme is NAMPT (nicotinamide phosphoribosyltransferase), which converts nicotinamide to NMN.

In lean adipose tissue, NNMT is expressed at low levels and the salvage pathway operates efficiently, maintaining NAD⁺ pools. In obese adipose tissue, NNMT is upregulated, diverting nicotinamide away from NAMPT and into MNA. The result is a relative NAD⁺ deficit even when dietary niacin intake is adequate. Because NAD⁺ is required for sirtuin deacetylases, PARPs, and numerous redox reactions, this depletion has cascading consequences for mitochondrial function, insulin sensitivity, and adipokine secretion.

The methyl-donor drain#

SAM is the universal methyl donor for most cellular methylation reactions, including DNA methylation, histone methylation, and phospholipid methylation. When NNMT consumes SAM to produce MNA, the cell must regenerate SAM through the methionine cycle, a process that requires ATP, folate, and vitamin B12. In adipocytes with chronically elevated NNMT, this regenerative burden taxes the one-carbon pool and raises homocysteine. The SAH that accumulates as a by-product is a potent product inhibitor of most methyltransferases, further depressing the global methylation capacity of the cell.

5-Amino-1MQ interrupts this cycle at the source. By blocking NNMT, it spares nicotinamide for the salvage pathway, preserves SAM for other methyltransferases, and prevents SAH accumulation. The net effect is a metabolically healthier adipocyte with restored NAD⁺/NADH and SAM/SAH ratios.

Beta-oxidation and mitochondrial respiration#

Restored NAD⁺ pools improve mitochondrial function. NAD⁺ is a substrate for sirtuins (particularly SIRT1 and SIRT3), which deacetylate and activate PGC-1α and mitochondrial respiration complexes. In preclinical models, NNMT inhibition increases oxygen consumption in adipocytes and shifts fuel utilisation toward fatty-acid oxidation. This is not a direct lipolytic effect on the cell membrane; it is an intracellular metabolic correction that changes how the adipocyte processes available lipid stores.

Insulin signalling#

Several studies have shown that NNMT knockdown or pharmacological inhibition improves insulin-stimulated Akt phosphorylation and glucose uptake in adipocytes. The mechanism is likely multifactorial: better mitochondrial ATP production, reduced inflammation via improved NAD⁺-dependent signalling, and favourable shifts in adipokine secretion (lower resistin and higher adiponectin) have all been reported. For researchers studying insulin resistance in obesity models, 5-Amino-1MQ offers a tool that targets the adipocyte intrinsically rather than acting on systemic appetite or gastro-intestinal transit.

NAD+ precursors versus NNMT inhibition: why the distinction matters for research design#

A common conceptual error is to assume that raising NAD⁺ is a unitary goal and that all compounds that accomplish it are mechanistically equivalent. They are not. NAD⁺ precursors such as nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) act by flooding the salvage pathway with substrate. They increase the flux through NAMPT by providing more nicotinamide, effectively pushing the reaction forward via mass action. In contrast, 5-Amino-1MQ raises NAD⁺ by removing a metabolic sink—blocking NNMT so that the nicotinamide already present in the cell is shunted toward NAMPT rather than toward MNA.

The distinction has practical consequences for experimental design. In a cell-culture model, NMN supplementation typically raises NAD⁺ within hours because the cell membrane expresses equilibrative nucleoside transporters and the NMN is converted to NAD⁺ directly by NMNAT enzymes. 5-Amino-1MQ, however, requires a longer equilibration time because its effect depends on the pre-existing rate of NNMT activity and the steady-state turnover of the nicotinamide pool. A researcher who treats adipocytes with 5-Amino-1MQ for two hours and sees no NAD⁺ rise may conclude the compound is inactive, when in reality the effect requires continued inhibition over twenty-four to forty-eight hours to deplete the accumulated MNA and allow NAD⁺ to rebuild.

The second consequence is specificity. NMN and NR raise NAD⁺ in virtually all tissues that express the relevant transporters and kinases. 5-Amino-1MQ's effect is concentrated in tissues with high NNMT expression—principally white adipose tissue, liver, and some cancer cell lines—making it a more targeted tool for adipocyte-centric studies.

The third consequence concerns combination logic. Combining an NAD⁺ precursor with an NNMT inhibitor is pharmacologically rational: the precursor increases substrate availability, while the inhibitor prevents substrate diversion. In a well-designed study, a triple arm (vehicle, precursor alone, inhibitor alone, combination) could test whether the effects are additive or synergistic. Such a design has not yet been published for 5-Amino-1MQ, and it represents a genuine gap in the literature.

Preclinical evidence: murine obesity, adipocyte biology, and selectivity#

The 5-Amino-1MQ literature is small but high-quality. The foundational paper is Neelakantan et al. (2017), published in Biochemical Pharmacology, and the follow-up validation by the same group in diet-induced obesity models is the strongest evidence currently available.

In vitro adipocyte studies#

Using 3T3-L1 pre-adipocytes and differentiated adipocytes, the authors showed that NNMT expression rises approximately 37-fold during adipogenesis. Baseline intracellular MNA was 7.5-fold higher in differentiated adipocytes than in pre-adipocytes, confirming that adipogenesis itself creates the substrate environment for NNMT activity.

Treatment with 5-Amino-1MQ reduced intracellular MNA in a concentration-dependent manner, with an EC₅₀ of approximately 2.3 µM. At 10 µM, the compound significantly increased intracellular NAD⁺ levels. At 30 µM, it significantly increased SAM. Importantly, nicotinamide levels and SAH levels were unchanged, indicating that the compound was selective for NNMT inhibition rather than broadly perturbing the methionine cycle.

Cell viability was unaffected up to 100 µM, with modest cytotoxicity appearing only above 300 µM. For researchers, this suggests a reasonable therapeutic window in cellular models, though cellular potency does not translate directly to in vivo dosing.

In vivo diet-induced obesity model#

Male C57Bl/6 mice were rendered obese by 11 weeks of high-fat diet (45% kcal from fat). They were then randomised to vehicle or 5-Amino-1MQ (20 mg/kg via subcutaneous injection, three times daily) for 11 days. The results were striking:

• Body weight: Vehicle-treated mice gained 0.6 g (~1.4%), while 5-Amino-1MQ-treated mice lost 2.0 g (~5.1%). The difference was highly significant (P < 0.0001 on days 9–10).
• Food intake: Cumulative food intake was modestly but significantly reduced (26.2 g versus 28.1 g; P < 0.05), suggesting a partial anorexic effect, though the magnitude of the change was smaller than the body-weight divergence, implying additional metabolic mechanisms beyond caloric restriction.
• White adipose tissue: Epididymal WAT mass fell by approximately 30% relative to body weight in treated mice, with a clear reduction in adipocyte size on H&E staining.
• Plasma lipids: Triglycerides and non-esterified fatty acids were reduced in treated animals.
• Glucose tolerance: An intraperitoneal glucose tolerance test showed improved glucose clearance in the treatment group.

These data support the hypothesis that NNMT inhibition in adipose tissue produces meaningful metabolic improvement in obesity, even with short treatment duration.

Selectivity and off-target profile#

A critical strength of the 5-Amino-1MQ data set is the selectivity panel. The compound was tested against structurally and functionally related enzymes by Reaction Biology Corporation:

• DNA methyltransferase 1 (DNMT1): No inhibition up to 200–600 µM.
• Protein arginine methyltransferase 3 (PRMT3): No inhibition up to 600 µM.
• Catechol O-methyltransferase (COMT): Less than 20% inhibition at maximum concentrations tested; no reliable IC₅₀.
• NAMPT: No inhibition up to concentrations greater than 100 µM.
• SIRT1: No inhibition up to 300 µM.

The selectivity is attributed to the compound's interaction with the nicotinamide-binding pocket of NNMT rather than the conserved SAM-binding pocket shared by most other methyltransferases. For researchers, this profile is reassuring: 5-Amino-1MQ appears to be a genuine NNMT inhibitor rather than a promiscuous methyltransferase poison.

Limitations of the preclinical data#

Despite the quality of the evidence, several limitations must be acknowledged. First, the in vivo study duration was only 11 days. Long-term effects on adipose tissue remodelling, systemic inflammation, and metabolic adaptation are unknown. Second, the route was subcutaneous injection three times daily—a practical burden that complicates translational relevance if oral bioavailability is poor. Third, the model was male mice only; sex-specific differences in NNMT expression and metabolic response have not been characterised. Fourth, there are no published combination studies with other metabolic agents, so additivity or synergy with GLP-1 agonists, exercise, or caloric restriction remains speculative.

Comparison with other metabolic research compounds#

5-Amino-1MQ is often discussed alongside GLP-1 peptides, incretin triple agonists, and GH fragments in online research communities, but those comparisons are mechanistically weak. The table below clarifies the positioning.

For Canadian researchers, the practical implication is that 5-Amino-1MQ should be treated as a mechanistic tool for adipocyte intracellular metabolism rather than as a competitor or substitute for GLP-1-based compounds. A research programme that includes both a systemic appetite suppressor and an intracellular metabolic corrector would test complementary mechanisms, but those mechanisms should not be conflated in protocol design or data interpretation.

Storage, handling, and analytical pitfalls#

Small-molecule quinolinium salts require different handling protocols from lyophilised peptides, and Canadian researchers who are accustomed to peptide storage may overlook critical stability considerations.

Temperature and moisture sensitivity#

Unlike most lyophilised peptides, which require refrigeration at -20 °C, 5-Amino-1MQ as a dry quinolinium salt is generally stable at ambient temperature for months if kept in a tightly sealed container with a desiccant. The primary degradation pathway is not hydrolysis or oxidation in the same way that peptides undergo backbone cleavage; rather, the main risks are hydration (which can lead to clumping and variable dosing if the material is weighed rather than dissolved) and photochemical degradation under prolonged UV exposure. The quinolinium chromophore absorbs strongly in the UV-A range, and photodegradation can generate coloured impurities that would be detectable by HPLC but may not alter the gross appearance of the powder until significant decomposition has occurred.

Recommended storage is:

1. Sealed amber vial or aluminium-laminate pouch with silica gel desiccant.
2. Room temperature (15–25 °C) in a dark cabinet, protected from direct sunlight and laboratory UV sources.
3. Avoid repeated freeze-thaw cycles if reconstituted in solution; prepare single-use aliquots in amber microcentrifuge tubes.

For solution preparation, solubility depends on the counter-ion. The chloride salt is freely soluble in water at concentrations of at least 50 mg/mL. The iodide salt is less water-soluble and may require brief sonication or warming to 37 °C to dissolve fully. DMSO is an acceptable co-solvent for stock solutions but should not exceed 10% v/v in the final injectable formulation for animal studies because DMSO can cause haemolysis at higher concentrations.

Analytical verification pitfalls#

The most common analytical error with 5-Amino-1MQ is assuming that a single HPLC purity value tells the complete story. Because the compound is ionic, standard reversed-phase C18 methods often produce broad peaks, poor retention, or ion-exclusion effects that make quantification unreliable. A COA that reports 98% purity by C18 HPLC without mentioning ion-pairing conditions or the buffer system used may be masking significant impurities that co-elute with the main peak or are entirely excluded from the column.

Researchers should request:

1. Method transparency: The HPLC method should state whether ion-pairing reagents (HFBA, TFA at ≥0.1%) were used, whether the column was end-capped C18 or a polar-embedded alternative, and what the gradient conditions were.
2. Peak purity assessment: Diode-array detection (DAD) or UV spectral homogeneity across the peak should confirm that the main peak is photometrically pure. A single-wavelength UV trace at 254 nm may miss impurities with different chromophores.
3. Mass balance: The COA should include mass-balance data (total recovery from the HPLC run) because ionic compounds can adsorb to stainless-steel frits or PEEK tubing, leading to artificially low purity if injection recovery is poor.
4. Chiral integrity: Although 5-Amino-1MQ is achiral at the quaternary nitrogen, some synthetic routes may generate positional isomers (e.g., 7-amino-1MQ) that are difficult to separate on standard C18 but readily distinguishable by NMR or high-resolution MS.

Counter-ion variability and dosing#

The bioactivity of 5-Amino-1MQ is driven by the free cation (the quinolinium species), but the counter-ion affects solubility, hygroscopicity, and local tissue tolerance after injection. Chloride is the most common salt form in research supply because of its low cost and excellent water solubility. Iodide is more hygroscopic and may cause local irritation at injection sites in small animals. Bromide falls between the two. If a researcher switches suppliers and the counter-ion changes, the mass-to-mole conversion must be recalculated because the molecular weight differs by the mass of the halide.

For example:

• 5-Amino-1MQ free base: 158.20 g/mol
• 5-Amino-1MQ chloride salt: 194.65 g/mol
• 5-Amino-1MQ iodide salt: 286.10 g/mol

A protocol written for 20 mg/kg of free-base equivalent requires 24.6 mg/kg of the chloride salt but 36.1 mg/kg of the iodide salt. Failing to account for this difference is a common source of protocol inconsistency.

Translational considerations and knowledge gaps#

Because 5-Amino-1MQ has never entered human clinical trials, the gap between preclinical findings and human relevance is large and must be acknowledged explicitly in any research planning.

Pharmacokinetic unknowns#

The published murine data used subcutaneous injection three times daily at 20 mg/kg. That dosing frequency suggests a short elimination half-life in rodents, which is consistent with the small molecular size and likely rapid renal clearance. However, no formal pharmacokinetic study has been published. Key unknowns include:

1. Bioavailability: What fraction of a subcutaneous dose reaches systemic circulation? Is subcutaneous absorption limited by local precipitation or tissue binding?
2. Distribution: Does 5-Amino-1MQ distribute into adipose tissue at concentrations sufficient to inhibit NNMT, or does it remain predominantly in the plasma and extracellular fluid?
3. Metabolism: Is the compound metabolised by hepatic enzymes, or is it cleared largely intact by the kidneys? The lack of published metabolite identification is a gap.
4. Half-life in larger species: Extrapolation from mouse to human using allometric scaling suggests that a t.i.d. schedule in mice might translate to once or twice daily in humans, but this is speculative without actual PK data.

Safety pharmacology gaps#

The Neelakantan study reported no adverse effects on gross behaviour or organ weights at the doses and duration tested, but that is not a comprehensive safety package. Missing data include:

1. Cardiovascular safety: No telemetry, ECG, or blood-pressure data have been published. Quinolinium derivatives as a class can have arrhythmogenic potential at high doses, and cardiac safety should not be assumed.
2. Hepatic and renal toxicity: No histopathology of liver or kidney after repeated dosing.
3. Reproductive toxicity: No data in pregnant animals or developmental studies.
4. Genotoxicity: The Ames test and chromosome aberration data were not reported in the 2017 paper. Quinolinium compounds can intercalate DNA, and genotoxicity screening is warranted before any progression toward more advanced research models.

For Canadian researchers, the implication is clear: 5-Amino-1MQ is an early-stage mechanistic tool. It should be used in well-powered preclinical studies with appropriate safety monitoring, but it is not a compound for which human-equivalent dose confidence exists.

Regulatory and compliance framing in Canada#

5-Amino-1MQ is not approved by Health Canada for any therapeutic indication. It is not listed as a natural health product. It is not a prescription drug. It is a research chemical that sits in the same regulatory grey zone as many synthetic peptides and small molecules sold for laboratory use.

Health Canada and research chemicals#

Under Canada's Food and Drugs Act, a substance that is not approved as a drug and is not marketed with therapeutic claims can generally be sold for research purposes, provided it is explicitly labelled as research-use-only and not represented as a treatment, preventative, or diagnostic agent. However, the line between "research chemical" and "unapproved drug" is enforced actively when suppliers make health claims, provide dosing instructions for humans, or market to consumers rather than laboratories.

For Canadian researchers, the relevant considerations are:

1. Explicit RUO labelling: The supplier must state that the product is for laboratory research only and not for human consumption.
2. Absence of therapeutic claims: Product pages should not mention weight loss, fat burning, anti-ageing, or disease treatment in humans.
3. Laboratory-grade documentation: COA, MS data, and stability information should be available.
4. SDS availability: A safety data sheet for handling should be provided, because quinolinium salts have known hazards (skin and eye irritation, potential mutagenicity in some congeners).

WADA and sport#

5-Amino-1MQ is not currently listed on the WADA Prohibited List. However, WADA's S0 category (Non-Approved Substances) captures any pharmacological substance not approved by any governmental regulatory health authority for human therapeutic use. Because 5-Amino-1MQ has no regulatory approval, it could theoretically fall under S0 if evidence emerges of performance enhancement or if WADA issues a specific statement. Researchers working with athletic populations should treat the compound as potentially prohibited and avoid performance-endpoint studies where anti-doping compliance is required.

Sourcing 5-Amino-1MQ: COA, purity, and supplier red flags#

Canadian researchers sourcing 5-Amino-1MQ face a market that is less mature than the GLP-1 peptide supply chain. Fewer suppliers carry the compound, analytical standards are less standardised, and counter-ion variation can introduce batch-to-batch inconsistency.

Minimum COA expectations#

1. HPLC purity: A chromatogram with stated method conditions (column, mobile phase, detector wavelength), principal peak integration, and lot number.
2. Mass spectrometry: Confirmation of the expected cationic species and counter-ion pattern.
3. NMR data: At minimum, a 1H NMR spectrum showing characteristic aromatic and methyl signals.
4. Counter-ion identity: Explicit statement of whether the material is supplied as chloride, bromide, iodide, or another salt.
5. Residual solvent screening: Particularly for methanol, ether, DMF, and acetonitrile.
6. Heavy-metal screening: Arsenic, lead, cadmium, and mercury should be below standard pharmaceutical limits.
7. Net content: The stated mass should refer to the free base equivalent or the total salt mass, clearly labelled.

Supplier red flags#

• A product page that describes 5-Amino-1MQ as a "fat burner," "weight-loss supplement," or "metabolic enhancer" for human use.
• Absence of batch-specific analytical data.
• Vague labelling such as "1MQ powder" without positional isomer specification or counter-ion information.
• Pricing that is substantially lower than comparable niche small molecules (a signal of impurity, mislabelling, or dilution).
• Marketing to fitness or bodybuilding communities rather than laboratories.

Lynx Labs lists 5-Amino-1MQ in its weight-management category and is the domestic supplier Northern Compound currently points readers toward for Canadian research-source evaluation. That recommendation is based on consistent batch documentation, domestic fulfilment, and transparent outbound link attribution. Researchers should still verify the current lot's COA independently before using any material in an experiment.

Designing better 5-Amino-1MQ studies#

Because 5-Amino-1MQ is preclinical and its human data are nonexistent, the most valuable research questions are mechanistic rather than efficacy-oriented. A well-designed study should exploit the compound's specific features and avoid treating it as a generic metabolic stimulant.

Adipose-tissue mechanistic studies#

The core hypothesis is that NNMT inhibition restores NAD⁺ and SAM in adipocytes. A strong protocol would measure:

• Intracellular NAD⁺, NMN, and nicotinamide by LC-MS/MS.
• Intracellular SAM, SAH, and the SAM/SAH ratio.
• NNMT protein expression and activity in isolated adipocytes.
• Sirtuin activity (SIRT1, SIRT3) by acetylated substrate turnover.
• Mitochondrial respiration by Seahorse extracellular flux analysis.
• Lipolysis rates (glycerol and NEFA release) under basal and stimulated conditions.

Comparative designs#

A useful comparator arm would use a structurally related but inactive analog (such as unsubstituted 1-MQ at a matched concentration, or a known inactive positional isomer) to confirm target engagement. A second comparator might use an NAD⁺ precursor such as NMN to test whether the metabolic improvements are specific to NNMT inhibition or merely a consequence of NAD⁺ replenishment.

Combination studies#

Because 5-Amino-1MQ acts intracellularly while GLP-1 agonists act systemically, a combination study in DIO mice could test whether the two mechanisms are additive. The hypothesis would be that GLP-1-driven caloric deficit creates a larger adipose-tissue substrate pool, while NNMT inhibition improves the metabolic quality of the remaining adipocytes. Such a study would require careful attention to dosing schedules, route compatibility, and food-intake monitoring to disentangle additive from synergistic effects.

Sex and strain stratification#

The published data are limited to male C57Bl/6 mice. Obese female mice, different strains (e.g., DIO on a C57Bl/6J versus DBA background), and genetically modified models (e.g., adipose-specific NNMT knockout) would strengthen the translational relevance of the findings.

NNMT biology beyond adipose tissue: liver, skeletal muscle, and cancer#

While the weight-management framing of 5-Amino-1MQ focuses naturally on white adipose tissue, the biology of NNMT extends into several other tissues that may be relevant to a broader Canadian metabolic research programme. Understanding these extensions prevents the narrow assumption that NNMT inhibition is exclusively an anti-obesity mechanism.

NNMT in the liver#

Hepatic NNMT expression is modest in healthy liver but becomes markedly elevated in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The mechanism is similar to adipose tissue: elevated NNMT diverts nicotinamide away from the salvage pathway, lowers hepatic NAD⁺, impairs sirtuin activity, and compromises mitochondrial beta-oxidation. The result is increased hepatic lipid accumulation, inflammation, and fibrogenic signalling. For researchers studying NASH models, 5-Amino-1MQ offers a liver-specific metabolic intervention that does not require the systemic exposure and appetite effects of GLP-1 agonists. However, the published mouse data did not examine hepatic histology or NAFLD activity scores, so this application is currently hypothetical.

NNMT in skeletal muscle#

Skeletal muscle expresses NNMT at lower levels than white adipose tissue, but expression rises with ageing and in models of sarcopenia. The metabolic consequence is a local NAD⁺ deficit that impairs SIRT1 and PGC-1α activity, reducing oxidative capacity and mitochondrial biogenesis. Theoretically, NNMT inhibition in muscle could improve insulin sensitivity and oxidative metabolism, but no published study has tested 5-Amino-1MQ in a muscle-specific knockout or overexpression model. For researchers interested in metabolic ageing or sarcopenia, this gap represents an opportunity rather than a settled conclusion.

NNMT in cancer#

A separate and rapidly growing literature connects NNMT overexpression to poor prognosis in several solid tumours, including pancreatic cancer, gastric cancer, and oesophageal squamous cell carcinoma. The mechanism is not merely metabolic; NNMT-driven depletion of SAM and elevation of SAH alters DNA and histone methylation patterns, promoting an epigenetic state favourable to tumour progression. Ulanovskaya et al. (2013) demonstrated that NNMT knockdown in cancer cell lines restored normal methylation patterns and reduced tumorigenicity. 5-Amino-1MQ has not been tested in oncology models, and the quinolinium scaffold raises theoretical genotoxicity concerns that would need to be addressed before any tumour research. The point is simply that NNMT biology is broader than adipose tissue, and the compound's research identity should not be confined to a single tissue context.

The medicinal-chemistry lineage: from 1-MQ to 5-Amino-1MQ#

The structural evolution of 5-Amino-1MQ is worth understanding because it illustrates how a weak, impermeable lead can be transformed into a viable tool compound through positional chemistry.

1-Methylquinolinium (1-MQ) was the original scaffold. It is a simple quaternary ammonium compound that binds the nicotinamide pocket of NNMT with an IC₅₀ of approximately 12.1 µM. The binding is detectable but weak, and more importantly, 1-MQ is essentially impermeable to biological membranes. In cell culture, it cannot access the cytosolic NNMT enzyme unless the cell membrane is disrupted, which limits its utility in intact-cell or in vivo experiments.

The breakthrough came with structure-based design. The NNMT active site accommodates the quinolinium ring in a deep pocket adjacent to the SAM cosubstrate. Computational modelling suggested that a primary amine at the 5-position of the quinoline ring would project into a solvent-exposed region without steric clash, while simultaneously improving the compound's polar surface area and hydrogen-bonding capacity enough to enhance membrane permeability without destroying target binding.

The experimental validation confirmed the prediction. 5-Amino-1MQ retained sub-micromolar potency (IC₅₀ 1.2 µM) while gaining high membrane permeability in both PAMPA and Caco-2 assays. The 7-amino positional isomer achieved a similar profile (IC₅₀ 2.6 µM), confirming that the amine substitution effect was not unique to the 5-position but was generalisable to the benzenoid ring of the quinoline system.

For researchers, the medicinal-chemistry story has two practical implications. First, it explains why 5-Amino-1MQ is active in intact cells while 1-MQ is not: the permeability gain is the critical difference. Second, it raises a caution about analogues. Any supplier offering an unsubstituted 1-MQ or a substituted quinolinium with the amine at a different position (e.g., 2-amino or 8-amino) should be viewed with skepticism, because those isomers may lack the same balance of potency and permeability.

5-Amino-1MQ in the broader Canadian metabolic research landscape#

The Canadian research peptide market has changed dramatically over the past three years. The arrival of Semaglutide and Tirzepatide brought a wave of clinical-grade supply-chain infrastructure—cold-chain shipping, batch-matched COAs, endotoxin testing, and formal stability protocols—that previously did not exist at scale for research peptides. That infrastructure benefits the entire market, including niche compounds like 5-Amino-1MQ, but it also creates a risk: researchers accustomed to the GLP-1 peptide paradigm may apply peptide-specific assumptions to a small molecule that behaves very differently.

Northern Compound's coverage of the weight-management category is deliberately broad. The archive includes pillar guides to Semaglutide and Tirzepatide, deep dives into AOD-9604 and MOTS-c, and comparison articles such as Semaglutide vs Tirzepatide. Each of these compounds targets a distinct node in energy-balance physiology. 5-Amino-1MQ adds the intracellular enzymatic layer—NAD⁺ salvage and one-carbon metabolism—that the receptor-focused compounds do not address. A research portfolio that spans appetite regulation, gastric motility, peripheral lipolysis, mitochondrial energetics, and intracellular methyl-donor status would capture the field more completely than any single-mechanism approach.

For Canadian labs, the practical implication is supply-chain diversification. Relying on a single supplier or a single compound category creates concentration risk. Health Canada enforcement actions, customs delays, or batch-specific quality failures can disrupt a research programme that lacks alternative sourcing channels. Including 5-Amino-1MQ in a broader metabolic research toolkit is not a recommendation to use it in isolation; it is a recommendation to understand its mechanism well enough to design studies that compare or combine it with other agents in a rigorous, hypothesis-driven framework.

Integration with existing Northern Compound content#

Researchers who are new to the weight-management archive may benefit from reading the content in sequence:

1. The Canadian research peptide buyer's guide establishes the regulatory and sourcing context that applies to all compounds discussed here.
2. The best weight-loss peptides for Canada comparison provides a high-level map of the dominant compounds and their relative trial maturity.
3. The AOD-9604 guide and MOTS-c guide cover metabolic mechanisms that are peripheral or mitochondrial rather than intracellular and enzymatic.
4. This 5-Amino-1MQ guide closes the loop by addressing the NAD⁺ salvage pathway, a node that sits upstream of many downstream metabolic phenotypes but is rarely discussed in peptide-focused literature.

Reconstitution and handling differences from peptides#

Researchers who are experienced with lyophilised peptides may need to adjust their handling workflow for 5-Amino-1MQ. The following practical notes are intended to prevent common errors during the transition between compound classes.

1. Weighing versus volumetric dosing: Small-molecule powders are typically dosed by mass rather than by reconstituted volume. A microbalance capable of 0.1 mg resolution is essential, because 5-Amino-1MQ is active at milligram-per-kilogram doses in murine models and sub-milligram errors can represent significant percentage deviations.
2. Vehicle selection: For subcutaneous injection in rodents, a simple buffered saline vehicle (PBS or sterile saline, pH 7.4) is usually sufficient for the chloride salt. The iodide salt may require brief warming or sonication. DMSO should be avoided in the final injectable because of haemolysis risk, though it is acceptable for stock preparation at low percentages.
3. Sterility: Unlike peptides, which are typically supplied lyophilised and sterile-filtered after reconstitution, small-molecule powders may not be manufactured under aseptic conditions. If the research protocol requires sterile material for in vivo use, the researcher may need to sterile-filter the reconstituted solution through a 0.22 µm PES membrane rather than assuming sterility from the vial.
4. pH adjustment: Quinolinium solutions are generally near-neutral because the cation is not strongly acidic or basic. However, if the synthesis残留 TFA or HCl is significant, the solution may be slightly acidic. pH should be checked with a microelectrode before injection and adjusted with sterile NaHCO₃ if necessary.
5. Light protection: All working solutions should be stored in amber vials or foil-wrapped tubes to prevent photochemical degradation. Even brief exposure to laboratory fluorescent lighting during preparation can generate measurable degradation over weeks.

Current Canadian supply status#

As of April 2026, 5-Amino-1MQ is available from a limited number of Canadian suppliers, but Lynx Labs lists it in its weight-management category with stated purity and domestic shipping. The market is less competitive than the GLP-1 segment, which means prices are higher per milligram and batch-to-batch variability may be greater because fewer manufacturers are producing the compound at scale. Northern Compound advises researchers to treat the first order from any supplier as a qualification batch: run the full analytical verification suite (HPLC, MS, NMR if available) before integrating the material into a long-term protocol.

Common mistakes in 5-Amino-1MQ interpretation#

The first mistake is conflating 5-Amino-1MQ with NAD⁺ precursors such as NMN, NR, or niacin. Those compounds raise NAD⁺ by increasing substrate availability. 5-Amino-1MQ raises NAD⁺ by blocking the enzyme that diverts the existing substrate away from the salvage pathway. The distinction matters for mechanistic studies, combination designs, and interpretation of metabolic outcomes.

The second mistake is extrapolating the 11-day mouse data to long-term human outcomes. The DIO mouse model produces rapid metabolic shifts that may not persist or translate into sustained weight loss in humans. No human safety or efficacy data exist, and the compound has not entered clinical development.

The third mistake is assuming that because NNMT is elevated in obese adipose tissue, it is the primary driver of obesity. NNMT is a downstream consequence of adipose tissue expansion and metabolic stress, not necessarily a causal initiator. Inhibiting it improves metabolic parameters in models, but it does not address the upstream drivers of caloric excess or physical inactivity.

The fourth mistake is ignoring the counter-ion. Different salt forms have different solubilities, stabilities, and toxicological profiles. A researcher who switches from chloride to iodide without re-characterising solubility and dosing may introduce uncontrolled variables.

The fifth mistake is sourcing from vendors who conflate 5-Amino-1MQ with quinoline-based disinfectants or unrelated quinolinium derivatives used in histology. The visual similarity of the name to compounds such as 1-methylquinolinium iodide (used in photodynamic research) creates potential mislabelling risk.

References and further reading#

• Neelakantan H. et al. "Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice." Biochemical Pharmacology (2017). PubMed.
• Kannt A. et al. "Nicotinamide N-methyltransferase knockdown in adipocytes increases energy expenditure and improves insulin sensitivity." Diabetes (2014). PubMed.
• Ulanovskaya O.A. et al. "NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sink." Nature Chemical Biology (2013). PubMed.
• Kraus D. et al. "Nicotinamide N-methyltransferase knockdown in adipocytes increases energy expenditure." Diabetes (2014). PubMed.
• Imai S., Guarente L. "NAD+ and sirtuins in aging and disease." Trends in Cell Biology (2014). PubMed.
• Yoshino J., Baur J.A., Imai S. "NAD+ intermediates: the biology and therapeutic potential of NMN and NR." Cell Metabolism (2018). PubMed.
• Li J. et al. "NNMT inhibition increases energy expenditure and promotes adipose tissue browning." Biochimica et Biophysica Acta (2018). PubMed.